Targeting CXCR4 to suppress glioma‐initiating cells and chemoresistance in glioma

Hu, Yu; Tang, Lingli; Yin, Senlin; Lv, Liang; Zhou, Peizhi

doi:10.1002/cbin.11836

Cited by 5 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the research conducted by Wu et al [14], it was discovered that increasing the expression of CXCR4 enhanced the migratory and invasive capabilities of U251 cells, which are brain glioma cells. The CXCR4regulated Akt pathway is an important link in promoting the growth and migration of tumor cells.…”

Section: Discussionmentioning

confidence: 99%

Predictive value of expression of the CXCR4/Akt signaling pathway in the peripheral blood for brain glioma

Zou

2024

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Background: The aim of this study was to investigate the activation of the C-X-C chemokine receptor type 4 (CXCR4)/Akt signaling pathway in the peripheral blood of individuals diagnosed with brain glioma and assess its potential as a predictive marker. Methods: A study was carried out on 120 patients diagnosed with brain glioma who were admitted between September 2015 and October 2016 (referred to as the brain glioma group). Additionally, a control group consisting of 100 healthy individuals who underwent physical examinations during the same time frame was included. According to the postoperative follow-up results, the patients with brain glioma were divided into death subgroup (n=30) and survival subgroup (n=85). Reverse transcription-polymerase chain reaction was used to identify the presence of molecules associated with the CXCR4/Akt signaling pathway in the peripheral blood samples. Results: The expressions of the CXCR4/Akt signaling pathway-related molecules differed significantly among tumor World Health Organization (WHO) grades and clinical outcome subgroups (P<0.05). The CXCR4 expression showed a significant correlation with the WHO grade of the tumor, Akt mRNA, E-cadherin, N-cadherin, and vimentin (P<0.05). The prognosis was significantly influenced by the elevated levels of CXCR4/Akt, tumor WHO grade, E-cadherin, N-cadherin, and vimentin, which acted as autonomous risk factors. The prognostic prediction accuracy of CXCR4/Akt was 90.48% for sensitivity and 94.87% for specificity, with a significant area under the receiver operating characteristic curve of 0.908 (P<0.05). Patients with high levels of CXCR4/Akt signaling pathway-related molecules had a considerably lower 5-year survival rate compared to those with low levels (21.08% vs. 46.37%, P<0.05). Conclusions: The expression of the CXCR4/Akt signaling pathway is significantly up-regulated in the peripheral blood of patients with brain glioma and is closely related to malignant tumor transformation.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive value of expression of the CXCR4/Akt signaling pathway in the peripheral blood for brain glioma

Zou

2024

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

show abstract

“…According to Ohtaki et al (2017) , ACTC1 is as an independent prognostic and aggressive marker of gliomas. In addition, Wu et al (2022) demonstrated that CXCR4 promotes the proliferation of GICs through the KLF5/BCL2L12-dependent pathway. These essential cluster genes may have good predictive efficacy for glioblastoma and are essential for glioblastoma development.…”

Section: Discussionmentioning

confidence: 99%

Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacology

Rao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Paclitaxel is an herbal active ingredient used in clinical practice that shows anti-tumor effects. However, its biological activity, mechanism, and cancer cell-killing effects remain unknown. Information on the chemical gene interactions of paclitaxel was obtained from the Comparative Toxicogenomics Database, SwishTargetPrediction, Binding DB, and TargetNet databases. Gene expression data were obtained from the GSE4290 dataset. Differential gene analysis, Kyoto Encyclopedia of Genes and Genomes, and Gene Ontology analyses were performed. Gene set enrichment analysis was performed to evaluate disease pathway activation; weighted gene co-expression network analysis with diff analysis was used to identify disease-associated genes, analyze differential genes, and identify drug targets via protein-protein interactions. The Molecular Complex Detection (MCODE) analysis of critical subgroup networks was conducted to identify essential genes affected by paclitaxel, assess crucial cluster gene expression differences in glioma versus standard samples, and perform receiver operator characteristic mapping. To evaluate the pharmacological targets and signaling pathways of paclitaxel in glioblastoma, the single-cell GSE148196 dataset was acquired from the Gene Expression Omnibus database and preprocessed using Seurat software. Based on the single-cell RNA-sequencing dataset, 24 cell clusters were identified, along with marker genes for the two different cell types in each cluster. Correlation analysis revealed that the mechanism of paclitaxel treatment involves effects on neurons. Paclitaxel may affect glioblastoma by improving glucose metabolism and processes involved in modulating immune function in the body.

show abstract

“…Among the several molecular signaling pathways, the expression of SDF-1α/CXCR4 is also a key determinant of other glioma subtypes, causing devasting tumor progression and invasiveness [ 141 ].…”

Section: Chemokine-targeting Therapies In Primary Brain Cancersmentioning

confidence: 99%

Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies

Ardizzone

Basilotta

Filippone

et al. 2023

Cells

View full text Add to dashboard Cite

Primary brain tumors are a leading cause of death worldwide and are characterized by extraordinary heterogeneity and high invasiveness. Current drug and radiotherapy therapies combined with surgical approaches tend to increase the five-year survival of affected patients, however, the overall mortality rate remains high, thus constituting a clinical challenge for which the discovery of new therapeutic strategies is needed. In this field, novel immunotherapy approaches, aimed at overcoming the complex immunosuppressive microenvironment, could represent a new method of treatment for central nervous system (CNS) tumors. Chemokines especially are a well-defined group of proteins that were so named due to their chemotactic properties of binding their receptors. Chemokines regulate the recruitment and/or tissue retention of immune cells as well as the mobilization of tumor cells that have undergone epithelial–mesenchymal transition, promoting tumor growth. On this basis, this review focuses on the function and involvement of chemokines and their receptors in primary brain tumors, specifically examining chemokine-targeting immunotherapies as one of the most promising strategies in neuro-oncology.

show abstract

Targeting CXCR4 to suppress glioma‐initiating cells and chemoresistance in glioma

Cited by 5 publications

References 49 publications

Predictive value of expression of the CXCR4/Akt signaling pathway in the peripheral blood for brain glioma

Predictive value of expression of the CXCR4/Akt signaling pathway in the peripheral blood for brain glioma

Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacology

Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies

Contact Info

Product

Resources

About